Phase 3 Study of DW-330SR2 and Pelubiprofen in Chronic Back Pain Patients
NCT ID: NCT02375633
Last Updated: 2016-10-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
166 participants
INTERVENTIONAL
2014-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase 1 Clinical Trial of DW340 and DW330SR + DW1030 Co-administration in Healthy Male Volunteers
NCT02380976
Pentoxifylline and Lumbar Radiculopathy
NCT03060434
Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
NCT05537571
Effect of PADMA 28 on Endothelial Function, Autonomic Nervous System and Biomarkers in Patients With Coronary Artery Disease
NCT01581034
Phase I Study of SB-480848(Darapladib) -Repeat Dose Study in Healthy Japanese Male Subjects-
NCT00622830
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DW-330SR2
DW-330SR(Pelubiprofen) 45mg twice a day
DW-330SR2
Pelubiprofen
Active Comparator(Pelubiprofen) 30mg three times a day
Pelubiprofen
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DW-330SR2
Pelubiprofen
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Class 1 or 2 back pain patients along Quebec Task Force Classification
* Patients with pain at least 40mm test results at visit2
* The voluntary or legal guardian 's written consent to participate in this clinical trial subjects
Exclusion Criteria
* Patients with secondary causes are obvious
* Within 24 weeks patient who has back surgery before clinical trial participation
* Within 4 weeks patient who experienced psychotropic drugs, a narcotic analgesic dosage that may affect the pain sensation
* Within 4 weeks patient who treated steroid drug by oral or injection
* Within 2 weeks patient who treated MAO inhibition drugs
* Patients with severe respiratory depression status
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daewon Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DW-330SR2_301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.